These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10915060)

  • 21. Renal and cardiovascular role of the neuropeptide Y Y1 receptor in ischaemic heart failure rats.
    Zhao XH; Sun XY; Bergdahl A; Edvinsson L; Hedner T
    J Pharm Pharmacol; 1999 Nov; 51(11):1257-65. PubMed ID: 10632083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropeptide Y suppresses epileptiform activity in rat frontal cortex and hippocampus in vitro via different NPY receptor subtypes.
    Bijak M
    Neurosci Lett; 1999 Jun; 268(3):115-8. PubMed ID: 10406018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
    Malmström RE
    Acta Physiol Scand Suppl; 1997; 636():1-55. PubMed ID: 9179320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [125I]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors.
    Widdowson PS; Buckingham R; Williams G
    Brain Res; 1997 Dec; 778(1):242-50. PubMed ID: 9462897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.
    Abounader R; Villemure JG; Hamel E
    Br J Pharmacol; 1995 Oct; 116(4):2245-50. PubMed ID: 8564255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
    Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
    Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N(G)-Acyl-argininamides as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity.
    Weiss S; Keller M; Bernhardt G; Buschauer A; König B
    Bioorg Med Chem; 2010 Sep; 18(17):6292-304. PubMed ID: 20688523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of Y receptors and signaling pathways in intestinal circular and longitudinal smooth muscle.
    Misra S; Mahavadi S; Grider JR; Murthy KS
    Regul Pept; 2005 Feb; 125(1-3):163-72. PubMed ID: 15582728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
    Pluym N; Baumeister P; Keller M; Bernhardt G; Buschauer A
    ChemMedChem; 2013 Apr; 8(4):587-93. PubMed ID: 23361914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dog saphenous vein: a sensitive and selective preparation for the Y2 receptor of neuropeptide Y.
    Pheng LH; Fournier A; Dumont Y; Quirion R; Regoli D
    Eur J Pharmacol; 1997 May; 327(2-3):163-7. PubMed ID: 9200555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rabbit ileum: a sensitive and selective preparation for the neuropeptide Y Y5 receptor.
    Pheng LH; Quirion R; Iyengar S; Fournier A; Regoli D
    Eur J Pharmacol; 1997 Aug; 333(2-3):R3-5. PubMed ID: 9314048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.
    Chu DQ; Cox HM; Costa SK; Herzog H; Brain SD
    Br J Pharmacol; 2003 Sep; 140(2):422-30. PubMed ID: 12970079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents.
    Wieland HA; Engel W; Eberlein W; Rudolf K; Doods HN
    Br J Pharmacol; 1998 Oct; 125(3):549-55. PubMed ID: 9806339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
    Kask A; Rägo L; Harro J
    Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plastic changes in neuropeptide Y receptor subtypes in experimental models of limbic seizures.
    Vezzani A; Moneta D; Mulé F; Ravizza T; Gobbi M; French-Mullen J
    Epilepsia; 2000; 41 Suppl 6():S115-21. PubMed ID: 10999532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats.
    Gradin KA; Buus CL; Li JY; Frøbert O; Simonsen U
    Br J Pharmacol; 2006 Jul; 148(5):703-13. PubMed ID: 16715120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
    Keller M; Erdmann D; Pop N; Pluym N; Teng S; Bernhardt G; Buschauer A
    Bioorg Med Chem; 2011 May; 19(9):2859-78. PubMed ID: 21493077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
    Keller M; Teng S; Bernhardt G; Buschauer A
    ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.
    Dumont Y; Gaudreau P; Mazzuferi M; Langlois D; Chabot JG; Fournier A; Simonato M; Quirion R
    Br J Pharmacol; 2005 Dec; 146(8):1069-81. PubMed ID: 16231000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.